Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“Dr. Alexander Drilon at WCLC26 presents 1L cohort of ARROS-1 trial of zidesamtinib in patients with ROS1 NSCLC.
What a waterfall plot. RR 94% with 15% CR. mPFS not reached, PFS at 6m was 96% and at 12m was 90%. Intracranial RR 100%. In 78 pts who did not have brain metastases at baseline, no CNS events occurred to date. These are fantastic outcomes.
WCLC26 Safety profile consistent with ROS1 selectivity. TRAEs in ≥15% of pts included edema, weight gain, blood CPK, dysgeusia, and AST elevation with few G3 TRAEs and discontinuation rate due to TEAE was 4%.”
You might be interested in:
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
